The Medtech industry earns only passing grades in the category of product design, according to product development group Nottingham Spirk. But the company hopes to leverage its experience and access …
HealthQuest Capital secured a $225 million fund to invest in new health care technologies. Managing Director Garheng Kong, MD, explains the firm’s views on health care, how doctors view new technolog…
Experienced medtech CEO Kerry Pope explains how the Fogarty Institute is building coalitions of corporations and entrepreneurs to create medtech start-ups.
Outset Medical CEO Leslie Trigg brings a career of success in medtech into a new approach to dialysis. Tablo, a sleek device, could enable dialysis companies an easier, cheaper way of providing dialy…
As CEO, Kevin Hykes led two companies – Visiogen and Cameron Health – to successful acquisitions by strategic acquirers. In this interview, Hykes shares the lessons learned from leading those compani…
Justin Klein, MD, JD, sits down with Healthegy TV to provide details on where his firm, New Enterprise Associates, sees the greatest opportunities in Medtech. He also explains how a firm with $3 bill…
For the past two decades, Josh Makower, MD, has sat on the innovator’s side of the table creating innovations and innovators through his work with the Exploramed incu-bator and Stanford Biodesign Pro…
Jason Lettman, partner at Lightstone Ventures, set up shop in Ireland after Lightstone closed its debut fund. Hear how he views Medtech from the other side of the Atlantic.
Oculeve, a stealthy start-up with backing from Kleiner, NEA and Versant, opted to sell its neurostim treatment for Dry Eye to Ophthalmology Leader Allergan.
Solace Therapeutics CEO Bill Gruber hopes to repeat the successful exit he helped execute when Hologic paid close to $300 million for his previous company Interlace.
Mark Leahey of the MDMA explains how a move against patent troll could cut the legs out from Medtech entrepreneurs and VCs dependent upon IP protection.
Matt Hermann, Senior Managing Director of Ascension Ventures, details how Pro-viders and Payer-sponsored investment firms have grown into influential investors in health care.
Vivo Capital, fresh off raising $750 million for its eight fund, has effectively strad-dled the Pacific, investing in life sciences in US and China. Managing Partner Chen Yu, MD, shares Vivo’s story …
Dennis Wahr, MD, CEO of Holaira Inc. and co-chair of the Medtech In-vesting Conference, says “the best is yet to come” for Medtech and shares his strategy for successful VC fund raising.
Intersect ENT CEO Lisa Earnhardt shares her perspective of ENT, the entire Medtech sector and how Intersect is outpacing its tech partners in one critical metric.
00:20:00 |
Wed 18 Mar 2015
Disclaimer: The podcast and artwork embedded on this page are the property of Healthegy. This content is not affiliated with or endorsed by eachpod.com.